http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9338854

Outgoing Links

Predicate Object
contentType Clinical Trial|Journal Article
endingPage 1229
issn 1029-2403
1042-8194
issueIdentifier 7
pageRange 1222-1229
publicationName Leukemia & Lymphoma
startingPage 1222
bibliographicCitation Dell'olio M, Potito scalzulli R, Sanpaolo G, Nobile M, Saverio mantuano F, La sala A, D'arena G, Miraglia E, Lucania A, Mastrullo L, Nicola C. Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma. 2011 May 25;52(7):1222–9. doi: 10.3109/10428194.2011.572321.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e05d868695807a4ea64c5ccf3b4c7d13
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_682365e454507ed78c99d74cd732a2fc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c78b19dd5599c224d228516bd04066f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1f1da7a1d3aab8bc66a7af66c1cc8014
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ac634286a6b487f48f0b5197550630cc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_43ef02f3c23f7c4080f980d3c1ac86be
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d0689c61cf221b7b4e1d1996a9655d08
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3bacf3fc565ff64080d7ea4c9534ff0d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d2bc12166d32f24f2ba88dfd54b04b62
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_af5a16ae87c0eefb63ad94d5ba47366f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2bcd30986c5af5137636c5b0cff47f16
date 2011-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.3109/10428194.2011.572321
https://pubmed.ncbi.nlm.nih.gov/21612383
isPartOf https://portal.issn.org/resource/ISSN/1029-2403
https://portal.issn.org/resource/ISSN/1042-8194
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2306
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma
discusses http://id.nlm.nih.gov/mesh/M0001348
http://id.nlm.nih.gov/mesh/M0006784
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D016403Q000188
http://id.nlm.nih.gov/mesh/D004317Q000627
http://id.nlm.nih.gov/mesh/D000903Q000627
hasSubjectTerm http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D000903Q000633
http://id.nlm.nih.gov/mesh/D016403Q000401
http://id.nlm.nih.gov/mesh/D016403Q000473
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D016277Q000187
http://id.nlm.nih.gov/mesh/D053208
http://id.nlm.nih.gov/mesh/D004317Q000008
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D000369
http://id.nlm.nih.gov/mesh/D000903Q000008
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D004317Q000633
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D009367
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11499
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5978
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71296921
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45358158
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134755071
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3717450
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6324671
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5388993
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID164145
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7920
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9859
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID50925403
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8390

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135789409

Total number of triples: 71.